Summary of the Conference Call for Kangfang Biopharma Company Overview - **Company**: Kangfang Biopharma - **Date**: March 27, 2026 Key Industry and Company Insights 1. Product and Market Access Achievements - In 2025, all five products of Kangfang Biopharma, covering 12 indications, were successfully included in the national medical insurance directory, significantly supporting sales growth in 2026 [2][5] - The commercial revenue for 2025 reached 3.033 billion yuan, marking a 51% increase year-on-year, primarily driven by two dual-antibody products [3][29] - The company expanded its commercial team to 1,500 people, doubling from approximately 800 in 2024, and achieved a 90% hospital access rate for its dual-antibody products [3][4] 2. Clinical Development and Product Pipeline - **Ivosidenib (PD-1/VEGF)**: Currently involved in 15 global Phase III clinical trials, with significant results expected in 2026. It is the only PD-1/VEGF dual antibody approved in the U.S. and has benefited around 70,000 patients [6][12] - **Kadonil (PD-1/CTLA-4)**: Demonstrated significant overall survival (OS) advantages in PD-L1 negative populations and is undergoing Phase III trials for first-line gastric cancer [6][15][17] - **Immunology Products**: The first self-developed product, Inokizumab (IL-12/23), was approved in 2025 for psoriasis and included in the national insurance directory [8] 3. Financial Performance - Total revenue for 2025 was 3.056 billion yuan, with a cash reserve of 9 billion yuan, indicating a strong financial position [29] - R&D expenditure was 1.575 billion yuan, with a decreasing R&D intensity ratio from 78% in 2023 to 52% in 2025, aiming for a target of around 25% [29] - The adjusted EBITDA loss narrowed to 191 million yuan, compared to a loss of 241 million yuan in 2024, reflecting improved financial health [29] 4. Strategic Collaborations and Future Plans - The company has partnered with Jichuan Pharmaceutical for the commercialization of its PCSK9 antibody, optimizing sales efficiency through external collaboration [10] - Future product launches are planned, with expectations for ten new products and over 25 indications in the next five years [31] 5. Technological Advancements - The company is upgrading its technology platform to "IO 2.0 + ADC 2.0," focusing on combining dual antibodies with antibody-drug conjugates (ADCs) to lead the next generation of cancer immunotherapy [4][11] - AI technology is being integrated across various business operations to enhance efficiency and quality in drug development [30][32] 6. Clinical Milestones and Regulatory Progress - Significant clinical milestones were achieved in 2025, including positive results from the HARMONi-A and HARMONi-3 studies, which are expected to enhance the credibility of Chinese innovative drugs in international markets [13][14] - The company is actively preparing for further international clinical trials and regulatory submissions, particularly for Ivosidenib and Kadonil in various indications [33][34] Additional Important Insights - The dual-antibody products are positioned as foundational therapies for future cancer treatment paradigms, with ongoing studies exploring their combination with ADCs and other novel therapies [19][28] - The company is also exploring innovative treatments in autoimmune diseases and central nervous system disorders, leveraging its dual-target antibody platform [21][22] This summary encapsulates the key points from the conference call, highlighting the company's achievements, strategic direction, and future outlook in the biopharmaceutical industry.

Core Viewpoint - Kangfang Biopharma reported a revenue of 1.412 billion yuan for the first half of 2025, marking a year-on-year increase of 37.75%, while the loss expanded to 588 million yuan from 249 million yuan in the same period last year [1][3] Financial Performance - Revenue for the period was 1.412 billion yuan, a 37.75% increase year-on-year [1] - Commercial sales revenue reached 1.402 billion yuan, up 49.20% year-on-year [1] - The company incurred a loss of 588 million yuan, which is an increase from the previous year's loss of 249 million yuan [1][3] Revenue Drivers - The growth in commercial sales revenue was primarily driven by the inclusion of AK104 and AK112 in the national medical insurance since January, leading to increased sales volume [1] - The increase in losses was attributed to a rise in equity investment losses from a partnership with Summit, which increased from 32.6 million yuan to 192 million yuan, as well as higher R&D expenses and stock incentive costs [3] Product Pipeline and Market Position - Kangfang Biopharma has received approval for seven products, including AK104 and AK112, which are key dual antibodies, and has expanded its commercial product range to include metabolic and autoimmune areas [4] - The sales team has grown from over 800 to 1,200 members, covering oncology and specialty drug sectors [4] - The company is focusing on AK112, which has shown promising results in clinical trials for non-small cell lung cancer [5][8] Clinical Development and Strategy - AK112 has achieved significant clinical endpoints in trials, including a statistically significant improvement in progression-free survival (PFS) [8][9] - The company is pursuing a strategy termed "IO2.0+ADC2.0," which aims to integrate dual antibodies with antibody-drug conjugates (ADCs) [12][13] - Kangfang Biopharma's pipeline includes ongoing clinical trials for various indications, with a focus on enhancing the efficacy of existing treatments [12][16]